CT Cardiomegaly vs EchoNext

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 65/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.

CT Cardiomegaly

by Innolitics

EchoNext

by Pathway Labs

AI Verdict

Both tools are FDA-cleared AI solutions in cardiology, but they differ in their primary focus and input data. CT Cardiomegaly analyzes CT chest images to measure cardiothoracic ratio for cardiomegaly detection, while EchoNext analyzes standard ECGs to detect hidden structural heart disease. Therefore, the choice depends on whether the user needs CT-based cardiomegaly assessment or ECG-based structural heart disease detection.

Choose CT Cardiomegaly if…

Choose CT Cardiomegaly if your institution primarily utilizes CT chest imaging and requires an automated, quantitative assessment of cardiothoracic ratio for cardiomegaly detection. This tool is ideal for radiology departments seeking a command-line solution that integrates with existing Docker environments and provides detailed PDF and JSON reports for further analysis and record-keeping.

View CT Cardiomegaly →

Choose EchoNext if…

Choose EchoNext if your clinical setting frequently uses standard 12-lead ECGs and you need an AI-powered solution to screen for hidden structural heart diseases like heart failure, valve disease, and pulmonary hypertension. This tool is best suited for practices looking for a non-invasive diagnostic support system that can be accessed through the OpenEvidence clinical decision support platform, offering broad applicability from major hospitals to community practices.

View EchoNext →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature	CT Cardiomegaly	EchoNext
Pricing	Contact for pricing	Starts at $600/month
Deployment	Docker Container (Ubuntu 20.04), command-line software	Available through the OpenEvidence clinical decision support platform.
BAA Available	Unknown	Yes AI-estimated
FDA Status	Yes AI-estimated	Yes AI-estimated
HIPAA	Yes AI-estimated	Yes AI-estimated

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

EchoNext

EchoNext is deployed through the OpenEvidence clinical decision support platform, suggesting a more integrated and potentially user-friendly experience within existing clinical workflows. CT Cardiomegaly is a command-line software, which typically requires more technical expertise and integration effort, making it less directly usable for most clinicians.

Clinical Value

EchoNext

EchoNext analyzes standard ECGs to detect a broad range of hidden structural heart diseases, including heart failure, valve disease, and pulmonary hypertension, and has demonstrated higher accuracy than cardiologists in studies. CT Cardiomegaly provides quantitative cardiothoracic ratio measurements from CT scans to assist in cardiomegaly detection, which is a more focused application.

Pricing & Value

EchoNext

EchoNext offers transparent tiered pricing starting at $600/month, including details on implementation fees and discounts, allowing potential users to better understand the cost. CT Cardiomegaly's pricing is 'contact for pricing,' which offers less transparency upfront. EchoNext's broad detection capabilities from a routine, inexpensive test like ECG also suggest a higher value proposition for widespread screening.

Enterprise Readiness

EchoNext

EchoNext's deployment through the OpenEvidence platform, which is used by 650,000 U.S. physicians, indicates strong enterprise readiness and existing integrations within healthcare systems. While CT Cardiomegaly is HIPAA compliant and offers a BAA, its Docker container and command-line deployment may require more significant IT resources for integration into large enterprise environments.

Innovation

EchoNext

EchoNext is described as the world's first FDA-cleared AI detection tool to analyze ECGs for hidden structural heart disease, representing a significant innovation in non-invasive cardiac screening. CT Cardiomegaly, while valuable, focuses on automated cardiothoracic ratio measurement, which is a more established application of AI in radiology.

Support & Docs

Tie

Both tools are FDA-cleared and HIPAA compliant, implying a certain level of documentation and regulatory support. However, specific details regarding ongoing customer support, training materials, or comprehensive documentation beyond regulatory compliance are not explicitly provided for either tool in the given information or readily available through web searches.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature	CT Cardiomegaly	EchoNext
Tool Name	CT Cardiomegaly	EchoNext
Company	Innolitics	Pathway Labs
Description	FDA-cleared AI-powered command-line software that automatically measures cardiothoracic ratio from CT chest images, assisting physicians in cardiomegaly detection with quantitative data.	FDA-cleared AI tool that analyzes standard ECGs to detect hidden structural heart disease, including heart failure, valve disease, and pulmonary hypertension.
Key Features	Automatic cardiothoracic ratio measurement, Machine learning algorithms for segmentation, Segmentation of heart and thoracic cavity, Calculates linear and area-based cardiothoracic ratios, Outputs PDF and JSON reports, Command-line software tool, Non-adaptive machine learning using MONAI framework, Validated against manual measurements by board-certified radiologists	AI-powered ECG analysis, Detection of hidden structural heart disease, Identifies heart failure risk, Screens for valve disease, Detects pulmonary hypertension indicators, Utilizes standard 12-lead ECGs, FDA-cleared technology, Non-invasive diagnostic support
Categories	Cardiology AI, Radiology & Imaging AI	Cardiology AI, Clinical Decision Support & Reference, Lab & Diagnostics
Specialties	Cardiology, Radiology	Cardiology, Family Medicine, Hospital Medicine, Internal Medicine

Videos

Demos, reviews, and walkthroughs featuring CT Cardiomegaly and EchoNext.

Loading videos…

Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

How do these tools integrate into existing clinical workflows and EHR systems?

CT Cardiomegaly is a command-line software designed to run independently or as part of another medical device, processing CT chest images to generate PDF and JSON reports. Innolitics emphasizes understanding DICOM, HL7, and FHIR for successful integration within hospital IT environments. EchoNext, on the other hand, is available through the OpenEvidence clinical decision support platform, which is used by over half of US clinicians, aiming to integrate its screening output directly into existing physician workflows at the point of care.

What is the accuracy and sensitivity of each tool in detecting cardiac conditions?

CT Cardiomegaly automatically measures cardiothoracic ratio with a mean difference of 0.0012 for CTR and 0.0036 for Heart to Chest Area Ratio when compared to manual measurements by board-certified radiologists. EchoNext, an AI-powered ECG model, demonstrated an AUROC of 85.2% and AUPRC of 78.5% in detecting structural heart disease in a study, outperforming cardiologists who achieved 64% accuracy alone and 69% with AI assistance.

For which specific cardiac specialties and conditions are these tools best suited?

CT Cardiomegaly is specifically designed for cardiology and radiology specialties, assisting in cardiomegaly detection by providing quantitative cardiothoracic ratio measurements from CT chest images. EchoNext is suitable for cardiology, family medicine, hospital medicine, and internal medicine, as it analyzes standard ECGs to detect hidden structural heart disease, including heart failure, valve disease, and pulmonary hypertension.

What is the typical learning curve for physicians to effectively use each tool?

CT Cardiomegaly is a command-line software that outputs PDF and JSON reports, suggesting a need for familiarity with integrating such outputs into a diagnostic review process. EchoNext is integrated into the OpenEvidence platform, implying that physicians familiar with this platform may experience a smoother learning curve.

What kind of support and resources are available for implementation and ongoing use?

Innolitics offers services including software development, FDA regulatory consulting, and cybersecurity support, and has experience with EHR and PACS integrations, suggesting comprehensive support for CT Cardiomegaly. Pathway Labs has partnered with OpenEvidence to make EchoNext widely available, indicating support through this platform, and aims to integrate the tool into real workflows across health systems at a national scale.

What audit-trail features are available to track the use and impact of these AI tools?

While specific audit-trail features are not detailed for CT Cardiomegaly, its nature as a command-line software outputting JSON reports suggests that the data and results could be integrated into systems with audit capabilities. For EchoNext, the integration with a clinical decision support platform like OpenEvidence could potentially leverage existing audit functionalities within that platform, though explicit audit-trail features for EchoNext itself are not specified.

How do these tools contribute to clinical decision-making beyond basic detection?

CT Cardiomegaly provides quantitative cardiothoracic ratio measurements, assisting physicians with objective data for cardiomegaly detection, which can inform further diagnostic work-up rather than providing a standalone diagnosis. EchoNext identifies hidden structural heart disease from standard ECGs, including heart failure, valve disease, and pulmonary hypertension, potentially enabling earlier detection and guiding decisions for follow-up imaging like echocardiograms, thereby streamlining patient care and potentially reducing diagnostic delays.